Targeting Mettl8-Tcf1 axis promotes CD8+ TPEX differentiation and antitumor immunity
Journal of Experimental Medicine · 04.05.2026 · 223 (5)
DOI: 10.1084/jem.20250424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 27.03.2026. Verfasst von Jiaxi Song und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Sc…. Hauptthemen laut MEDLINE: Hepatocyte Nuclear Factor 1-alpha, CD8-Positive T-Lymphocytes, Methyltransferases, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of China, Chinese Academy of Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
CD8+ T cell exhaustion represents a major obstacle to effective cancer immunotherapy. While stem-like progenitor exhausted T (TPEX) cells can differentiate into intermediate (Int-TEX) and terminally exhausted (TEX) subsets, the epigenetic regulation of this process is unclear. We identify the RNA methyltransferase Mettl8 as a critical regulator, with expression significantly higher in TPEX than in TEX subsets. In anti–PD-1 responding non-small cell lung cancer patients, Mettl8 and the stemness factor TCF7 were downregulated. In murine models, Mettl8 deletion restrained tumor progression by driving TPEX differentiation into effective Int-TEX cells. Mechanistically, Mettl8 stabilizes Tcf7 mRNA via m3C modification and enhances Tcf1 protein expression. Additionally, Mettl8 interacts with Tcf1 to facilitate chromatin looping at the Tox locus, maintaining TPEX stemness. Pharmacological Mettl8 inhibition promoted TPEX-to-Int-TEX differentiation and tumor control. Combining this inhibition with anti–PD-1 therapy yielded synergistic efficacy. Our findings establish Mettl8 as a pivotal regulator of TPEX fate and a promising therapeutic target for enhancing immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei, China.
- Guangzhou National Laboratory , Guangzhou, China.
- Institute of Immunological Innovation and Translation, Chongqing Medical University , Chongqing, China.
- Changping Laboratory , Beijing, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong…
ORCID-Profile: Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Qing Liu, Jing Yang, Haoyu Yu, Lilin Ye, Qizhao Huang, Jia Li, Fengyin Li
Förderung
- Ministry of Science and Technology of China
- Chinese Academy of Sciences
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- University of Science and Technology of China
- Guangzhou National Laboratory
- Natural Science Foundation of Chongqing
Zitieren
APA
Song, J., Cui, D., Wang, J., Qi, X., Ma, J., Liu, Q., Yang, J., Yu, H., Ye, L., Huang, Q., Li, J., & Li, F. (2026). Targeting Mettl8-Tcf1 axis promotes CD8+ TPEX differentiation and antitumor immunity. Journal of Experimental Medicine, 223(5). https://doi.org/10.1084/jem.20250424
Vancouver
Song J, Cui D, Wang J, Qi X, Ma J, Liu Q, et al. Targeting Mettl8-Tcf1 axis promotes CD8+ TPEX differentiation and antitumor immunity. Journal of Experimental Medicine. 2026;223(5). doi:10.1084/jem.20250424
BibTeX
@article{Song2026,
author = {Song, Jiaxi and Cui, Dan and Wang, Jiabao and Qi, Xuewei and Ma, Jiaxin and Liu, Qing and Yang, Jing and Yu, Haoyu and Ye, Lilin and Huang, Qizhao and Li, Jia and Li, Fengyin},
title = {Targeting Mettl8-Tcf1 axis promotes CD8+ TPEX differentiation and antitumor immunity},
journal = {Journal of Experimental Medicine},
year = {2026},
volume = {223},
number = {5},
doi = {10.1084/jem.20250424}
}
EUVIMED